Results 11 to 20 of about 691 (170)

Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain [PDF]

open access: yesOpen Biology, 2016
The vast majority of clinically approved protein kinase inhibitors target the ATP-binding pocket directly. Consequently, many inhibitors have broad selectivity profiles and most have significant off-target effects.
Selena G. Burgess   +6 more
doaj   +6 more sources

A Single-Domain VNAR Nanobody Binds with High-Affinity and Selectivity to the Heparin Pentasaccharide Fondaparinux [PDF]

open access: yesInternational Journal of Molecular Sciences
Glycosaminoglycans (GAGs) are key ligands for proteins involved in physiological and pathological processes. Specific GAG-binding patterns are rarely identified, with the heparin pentasaccharide as an Antithrombin-III ligand being the best characterized.
Martha Gschwandtner   +2 more
exaly   +5 more sources

Synthetic libraries of shark vNAR domains with different cysteine numbers within the CDR3.

open access: yesPLoS ONE, 2019
The variable domain of New Antigen Receptors (vNAR) from sharks, present special characteristics in comparison to the conventional antibody molecules such as: small size (12-15 kDa), thermal and chemical stability and great tissue penetration, that makes
Olivia Cabanillas-Bernal   +5 more
doaj   +4 more sources

Development and application of a VNAR-based detection nanobody for avian influenza virus H9N2 [PDF]

open access: yesFrontiers in Immunology
The H9N2 subtype avian influenza virus, as a mutant strain of low-pathogenic avian influenza (LPAI), has augmented its transmission ability and pathogenicity via genetic evolution.
Hongzhou Ye   +9 more
doaj   +3 more sources

Brain delivery of biologics using a cross‐species reactive transferrin receptor 1 VNAR shuttle [PDF]

open access: yesThe FASEB Journal, Volume 34, Issue 10, Page 13272-13283, October 2020., 2020
Abstract Transferrin receptor 1 (TfR1) mediated transcytosis is an attractive strategy to enhance brain uptake of protein drugs, but translation remains a challenge. Here, a single domain shark antibody VNAR fragment (TXB2) with similar affinity to murine and human TfR1 was used to shuttle protein cargo into the brain. TXB2 was fused to a human IgG1 Fc
Dag Sehlin   +6 more
wiley   +5 more sources

Identification of Anti-TNFα VNAR Single Domain Antibodies from Whitespotted Bambooshark (Chiloscyllium plagiosum)

open access: yesMarine Drugs, 2022
Tumor necrosis factor α (TNFα), an important clinical testing factor and drug target, can trigger serious autoimmune diseases and inflammation. Thus, the TNFα antibodies have great potential application in diagnostics and therapy fields.
Linfei Zhao   +5 more
doaj   +2 more sources

Yeast Surface Dual Display Platform for Rapid Discovery of Shark VNAR from a Semi-Synthetic Library Followed by Next-Generation Sequencing

open access: yesApplied Sciences, 2023
The shark-derived single-domain antibody VNAR (variable domain of new antigen receptor) has many advantageous features that make the VNAR suitable for improving current monoclonal antibody therapy deficiencies or disease diagnosis methods.
Chia-Hung Tsai   +3 more
doaj   +2 more sources

The influence of antibody humanization on shark variable domain (VNAR) binding site ensembles

open access: yesFrontiers in Immunology, 2022
Sharks and other cartilaginous fish produce new antigen receptor (IgNAR) antibodies, as key part of their humoral immune response and are the phylogenetically oldest living organisms that possess an immunoglobulin (Ig)-based adaptive immune system. IgNAR
Monica L. Fernández-Quintero   +5 more
doaj   +3 more sources

Identification and characterization of IgNAR and VNAR repertoire from the ocellate spot skate (Okamejei kenojei) [PDF]

open access: yesFrontiers in Marine Science, 2023
Elasmobranchs are crucial for comparative studies of evolution, as they belong to the most ancient vertebrate lineages that survived numerous extinction events and persist until today.
Jianqing Wen   +14 more
doaj   +2 more sources

A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy [PDF]

open access: yesActa Pharmaceutica Sinica B
TROP-2, a tumor-associated antigen, has been implicated in the progression of various epithelial tumors. Due to its favorable expression profile, TROP-2 has emerged as a promising target for antibody-drug conjugates (ADCs) based anti-tumor therapies. Although ADCs have shown efficacy in cancer treatment, their application in solid tumors is hindered by
Ming-Wei Wang, Qiang Wang, Zhicheng Zuo
exaly   +4 more sources

Home - About - Disclaimer - Privacy